Saturday 17 October 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024. In the quarter to June 2026, revenue fell 34.6%, EPS grew 78.1% and free cash flow fell 22.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.67
0.03
+4.69%
Follow COCH
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 9.61 | 9.66 | 0.75 | 1.08 | 0.64 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 10.00 | 10.05 | 11.72 | 11.46 | 1.91 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 2 | 34 | 42 | 47 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.12 | 0.01 | 0.01 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 0 | 0 | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | (110.13) | (149.68) | (229.78) | (262.66) | |||||
| EBT | — | — | — | — | 0 | 0 | (16) | (30) | (21) | (24) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (6,718.57) | (9,468.99) | (9,242.22) | (9,857.26) | |||||
| Net income | — | 0 | — | — | 0 | 0 | (16) | (30) | (21) | (24) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.02 | 0.03 | 0.01 | 0.01 | ||||
| Earnings | — | — | — | — | — | (0.02) | (1.57) | (2.38) | (1.49) | (1.23) | |||||
| Cash flow | — | — | — | — | 0.00 | (0.31) | (0.87) | (1.39) | (0.96) | (0.78) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.02) | (0.01) | (0.05) | (0.01) | |||||
| Free cash flow | — | — | — | — | 0.00 | (0.31) | (0.89) | (1.40) | (1.01) | (0.79) | |||||
| Book value | — | — | — | — | 0.00 | (3.47) | (3.58) | (0.14) | (1.00) | (0.52) | |||||
| Shares, m | — | — | — | — | 60 | 11 | 10 | 12 | 19 | 23 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 73.54 | 119.42 | 63.70 | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 174.39 | 190.19 | 175.25 | |||||
| EV/FCF | — | — | — | — | — | — | (15.46) | (3.20) | (2.26) | (2.30) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (3) | (9) | (17) | (18) | (18) | ||||
| Capex | — | — | — | — | 0 | — | 0 | 0 | (1) | 0 | |||||
| Free cash flow | — | — | — | — | 0 | (3) | (9) | (17) | (19) | (18) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | (2) | (1) | 0 | 1 | (5) | ||||
| Total debt | — | — | — | — | — | — | 33 | — | 19 | — | |||||
| Net debt | — | — | — | — | 0 | 0 | 33 | (4) | 13 | (4) | |||||
| Shareholders’ equity | — | — | — | — | 0 | (37) | (36) | (2) | (19) | (12) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (1.17) | (0.12) | (7.42) | (577.65) | (282.43) | (285.25) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | 1.37 | 43.68 | 164.71 | 271.35 | 184.92 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Envoy Medical, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MYO Myomo, Inc. | $51.5M | — (loss-making) | — (loss-making) | +21.26% (above 0%: growing) | n/m | +80.02% (above 0%: growing) | 72.13% | (19.26%) | Compare |
| COCH Envoy Medical, Inc. | $49.9M | — (loss-making) | — (loss-making) | −34.62% (below 0%: shrinking) | n/m | −22.44% (below 0%: shrinking) | (445.10%) | (10,919.61%) | |
| MDAI Spectral AI, Inc. | $49.6M | — (loss-making) | — (loss-making) | −30.42% (below 0%: shrinking) | n/m | −21.86% (below 0%: shrinking) | 31.58% | (122.70%) | Compare |
| TLIS Talis Biomedical Corporation | $46.3M | — (loss-making) | — (loss-making) | −94.01% (below 0%: shrinking) | n/m | +23.80% (above 0%: growing) | 91.78% | 0.00% | Compare |
| SRTS Sensus Healthcare, Inc. | $45.6M | — (loss-making) | — (loss-making) | −68.69% (below 0%: shrinking) | n/m | −201.65% (below 0%: shrinking) | 33.58% | (138.86%) | Compare |
| TELA TELA Bio, Inc. | $45.6M | — (loss-making) | — (loss-making) | −4.49% (below 0%: shrinking) | n/m | −17.72% (below 0%: shrinking) | 72.77% | (48.12%) | Compare |
| SNWV Sanuwave Health Inc. | $44.5M | 3.0× | — (loss-making) | −3.13% (below 0%: shrinking) | n/m | +86.75% (above 0%: growing) | 76.23% | (2.88%) | Compare |
| XTNT Xtant Medical Holdings, Inc. | $42.5M | — (loss-making) | — (loss-making) | −34.96% (below 0%: shrinking) | n/m | −881.96% (below 0%: shrinking) | 57.88% | (39.81%) | Compare |
| RPID Rapid Micro Biosystems, Inc. | $42.4M | — (loss-making) | — (loss-making) | +10.91% (above 0%: growing) | n/m | −23.97% (below 0%: shrinking) | 15.05% | (152.99%) | Compare |
| Median of peers | $45.6M | — | — | −17.45% | — | −19.79% | 65.01% | (43.96%) |
Envoy Medical, Inc. (COCH) key facts
- Strength: Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024.
- Envoy Medical, Inc. (COCH) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, COCH traded at $0.67, a market capitalization of $49.9 million.
- Return on equity was 184.9% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −60.12 (distress zone) for fiscal 2025.